Member Info for Billy-Bunter

I took a quick look at that. Its showing as me needing to subscribe to read the full article. Otherwise, I'm looking at the first couple of lines only.
Bill

I’m a 30 minute train ride away from central London. I think I’ll probably go.

P.S. is anyone on here intending to go to the AGM?
Bill

Tried to buy a further £10k of shares this afternoon, but I couldn’t make the trade. The largest size of could get was a lowly £1k. I’ll try again on Monday.

P.S. Does anyone have any ideas on where the share price could land with a fully working 230MeV system, the regulatory approvals in hand and the 6 sales all formally taken? I've got my own ideas, but I'm interested to know what others think.
I noted the recent Hardman & Co 161p fully diluted)analysis.
Bill

I just went in for another £10,000 . Now sitting on about 300,000 shares with a 30p average.
Hoping that the up and coming milestones will lift the share price.
Bill

Thank you, Potnak and HBD.
My prior working assumption had been late Q1 for the results. Obviously it would be great if they come within this year.
B.

Does anyone have a feel for how long its likely to take for the P1 data to be published? Lets assume the CTA is submitted at the end of this month, then two months for the CTA to be approved. Takes Sareum to the end of September. Assume then say a month lead in to starting the trials. End of October. So, how long then from that point to run the trial, collate the trial data and finally publish it?

Breaking news. Boris to step down, carrying on into the Autumn as caretaker PM.

Whilst it would be great to hear something later this month, I’m deliberately keeping my expectations low. If we hear something in the October GSK quarterly update, I’ll be delighted.

And, I agree with you , Potnak. It’s wasted energy at this stage going back over and over how things have played out with the CPF and Sierra. Things are where they are and focusing on GSK and how they operate is what matters now.

Bill.

Not quite right. GSK have to give the CPF an update within July/August. And, GSK will issue their next quarterly report at the end of July (this month) and update their pipeline at the same time.
Bill

Under the terms of the deal, the CPF will be due an update from GSK during the period July/August this year. Then again in January/February next year.

GSK did acknowledge SRA737, in one of their press releases announcing the acquisition.

https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-sierra-oncology-for-19bn/

Look half way down the document and you’ll see it.

Bill

Thanks, AParky. That is in line with my thinking. I actually just bought £10K of shares, and am mulling over a purchase of an additional £25K worth. On the basis that we will see a SP lift when these near-term milestones are met.
Bill.

What thoughts do other posters have on this BB regarding the possible need for another large fund raise by AVO?

It looks like AVO had about £4.5M on hand at the end of last year and have since raised a further £15M this year. Call its £20M. But, they are going through about £2.5M a month so I'm guessing they are down to about £5M in funds (please let me know if my calculations are off). And, a £10M loan coming due in November.

Assuming they get the FDA and CE approvals giving them a saleable system (plus of course the required 230MeV performance), I'm sure they will be able formally 'book' the proposed orders which may help the cash position. But even so, its looking like AVO will need some warrants to be exercised and issue more shares.

With the signals from the company on time lines for a fully working 230MeV system and regulatory approvals, I'm assuming they are hoping to get both these milestones in the bag, to see a increase in the share price (and probably more interest in AVO as a business) and then probably go for an additional large fund raise or other deal.

What do others on here think? I'm just trying to work out, is AVO likely at the share price bottom now, even accounting for some further dilution in the form of warrants and the issue of new shares once these near term targets have been met?

I've held some for about 5 years. But, I think that AVO could be entering a pivotal period and I'm tempted to buy a big block of additional shares at these prices.

Thank you, Vanilla

Yes, but no mention of SRA737 in that, or the accompanying press release.... :-(

Could someone please help me, and confirm what the status is of the CE approval for the Light system?

Yes, whilst it would be nice if GSK puts out some big announcement regarding SRA737, it doesn't seem to be how they operate having been back through every product update for the last several years.

I think things are going to go as follows:

1). GSK will put out and RNS and press release confirming the Sierra deal has closed. The press release will 'probably' only mention SRA737 as a Sierra pipeline asset. Though naturally it would be great if it gets a broader mention.

2). The next GSK quarterly report and pipeline update will be at the end of July, followed by another at the end of October. My very strong hope is that GSK add SRA737 to the oncology section of the pipeline as a P1 asset, on the basis that SRA737 has already completed a P1 safety study here in the UK.

3). If, as some on here think, that GSK will partner/license SRA737 to another pharma company (Zentalis, etc.) either entirely or for an additional oncology indication, that will likely follow on via an announcement after the next quarterly update,. Because I think to do it before then would be a bit quick, seeing how long a deal can take to put together.

Bill